-
Alliance for Regenerative Medicine Cell & Gene Therapy Investor Day on Thursday, April 27 , at2:45 p.m. ET at the State Room (60State Street ),Boston, Massachusetts -
Bank of America Merrill Lynch 2017 Healthcare Conference onWednesday, May 17 at4:20 p.m. PT at the Encore at the Wynn,Las Vegas, Nevada
To access the live webcast of bluebird bio’s presentations, please visit the “Calendar of Events” page within the Investors and Media section of the bluebird bio website at http://investor.bluebirdbio.com. Replays of the webcast will be available on the bluebird bio website for 90 days following the conference.
Forward-Looking Statements
This release contains “forward-looking statements” within the meaning
of the Private Securities Litigation Reform Act of 1995, including
statements regarding the Company’s product candidates and
research programs. Any forward-looking statements are based on
management’s current expectations of future events and are subject to a
number of risks and uncertainties that could cause actual results to
differ materially and adversely from those set forth in or implied by
such forward-looking statements. These risks and uncertainties include,
but are not limited to, risks that the preliminary results from our
clinical trials will not continue or be repeated in our ongoing clinical
trials, the risk of cessation or delay of any of the ongoing or planned
clinical studies and/or our development of our product candidates, the
risk of a delay in the enrollment of patients in our clinical studies,
risks that the current or planned clinical trials of the LentiGlobin
drug product will be insufficient to support regulatory submissions or
marketing approval in the
View source version on businesswire.com: http://www.businesswire.com/news/home/20170426006080/en/
Source: bluebird bio, Inc.
Investors:
bluebird bio, Inc.
Manisha Pai, 617-245-2107
mpai@bluebirdbio.com
or
Media:
bluebird
bio, Inc.
Elizabeth Pingpank, 617-914-8736
epingpank@bluebirdbio.com